Navigation Links
ESC recommends patients and centres for renal denervation

Sophia Antipolis, 24 April 2013: Up to 10 per cent of patients with high blood pressure are resistant to treatment, which puts them at increased risk of cardiovascular events, including heart attacks. Clinical trials show that catheter-based renal denervation reduces blood pressure in patients who do not respond to conventional drug therapy.

Use of the technique is increasing in Europe and worldwide and several national societies have published guidance on which patients with hypertension should receive treatment. The European Society of Cardiology (ESC) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) decided it was time for a European view and have developed an expert consensus document on catheter-based renal denervation.

The paper provides guidance on patient selection, centre selection, efficacy, safety, limitations and potential new indications for referring physicians, interventionalists and healthcare providers. It is published today in European Heart Journal, online ahead of print.1 [must confirm]

First author Dr Felix Mahfoud (Germany), said: "The hope is that insurance companies and healthcare providers will read it and will only pay for those centres and especially for those patients who fit the criteria published in the paper. The problem right now is that there are no European criteria for determining which patients are most likely to benefit and which centres have the necessary experience."

The technique involves radiofrequency ablation of the renal sympathetic nerves via a catheter. It resets renal blood pressure regulation and reduces whole body sympathetic nerve activity.

Increased activity of the sympathetic nervous system occurs in other conditions including heart failure, diabetes, arrhythmias, chronic kidney disease and obstructive sleep apnea, and pilot studies indicate that renal denervation may be an effective therapy.

Dr Mahfoud said: "We have known for decades that high sympathetic activity could be a target for treatment but until now we haven't had a way to do it. We now have a new treatment modality which allows us to reduce sympathetic activity and I'm optimistic that we will get new indications for renal denervation."

The paper states that renal denervation is currently indicated for blood pressure control in patients with treatment resistant hypertension (defined as systolic blood pressure >160mmHg or >150mmhg in type 2 diabetes) despite treatment with at least three antihypertensive drugs of different types in adequate doses, including one diuretic, and lifestyle modification. Screening should be conducted to exclude patients with secondary causes of hypertension that are potentially curable.

Centres should be specialised in the management of hypertension. At least one hypertension expert should be involved in treatment and screening and the intervention should be performed by interventional cardiologists or angiologists with training in percutaneous renal artery access. Centres should perform more than 25 renal artery interventions per year to ensure they have the required experience.

The Symplicity HTN-1 trial showed that renal denervation had a sustained blood pressure lowering effect over three years2 but longer efficacy data is needed. Dr Mahfoud said: "We treated the first patient three years ago and so far there is no sign of renervation. Long term follow up of these patients is needed."

Trials have not investigated the possibility of reducing pill burden. Dr Mahfoud said: "Patients have to keep taking their antihypertensive medications."


Contact: Jacqueline Partarrieu
European Society of Cardiology

Related medicine news :

1. New ASTRO white paper recommends best practices to improve safety and effectiveness of IGRT
2. QCI Mold and Water Damage Now Recommends All New Fiberlock HydroBoost Product to Commercial and Residential Clients
3. New Study from AAN: Herpes May Lead to Alzheimer’s Disease; polyDNA Recommends Gene-Eden-VIR Against the Herpes Virus
4. Worst Flu Season in a Decade; polyDNA Recommends Gene-Eden-VIR against the Flu Virus
5. MSSD Recommends UCSD Integrative Oncology Conference
6. Avanquest Recommends MOD, MOV, and MP4 Types of Software
7. New ASTRO white paper recommends peer review to increase quality assurance and safety
8. Study: Smoking Increases HPV Risks; polyDNA Recommends Gene-Eden-VIR Against HPV
9. Study: 15% of Children Ages 10 - 14 Consider Using Steroids; polyDNA Recommends Muxscle for Safe Muscle Building
10. Study: Steroid Abuse in Teens is Increasing; polyDNA Recommends Muxscle for Safe Muscle Building
11. Hudson Valley ENT Recommends Prepping Now for the 2013 Allergy Season
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/27/2016)... ... 27, 2016 , ... recently awarded their highest five-star rating to Best ... individuals in the United States and Canada wear eyeglasses. Once considered to be a ... and make a fashion statement. Even celebrities use glasses as a way of creating ...
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: